Over-the-counter vitamin K₁-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K₁-depleted patients

Summary

Most multivitamin supplements contain far less vitamin K₁ than thought to affect warfarin anticoagulation. Having described 3 patients with multivitamin-warfarin interactions, we hypothesized that vitamin K₁–depleted patients are sensitive to even small increments. Therefore, we compared the effect of a vitamin K₁-containing multivitamin on warfarin anticoagulation between patients with low versus normal vitamin K₁ status. We screened 102 warfarin-treated patients and recruited nine with “low” (< 1.5 mcg/L, 10^th percentile) (group 1) and 7 with “normal” (>4.5 mcg/L, median) (group 2) total vitamin K₁ plasma levels (vitamin K₁ + vitamin K₁ 2,3-epoxide). Patients received one multivitamin tablet containing 25 mcg of vitamin K₁ daily, for 4 weeks (period 1). A predefined algorithm was used to adjust warfarin doses if the INR was outside the therapeutic range. Patients requiring warfarin increments were then switched to 4 weeks of a vitamin K₁-free multivitamin supplement (period 2). During period 1, subtherapeutic INRs occurred in 9/9 and 1/7 patients in group 1 and 2, respectively (p <0.001). In group 1, INR decreased by a median of 0.51 (p <0.01), and warfarin dose had to be raised by 5.3% (p <0.01), whereas INR and warfarin dose did not change significantly in group 2. During period 2 (7 patients), there were trends towards decreased total vitamin K₁ and rising INRs associated with significantly lower warfarin doses. We conclude that vitamin K₁-containing multivitamins reduce INR in patients with low vitamin K₁ status. Our study suggests that vitamin Kdepleted patients are sensitive to even small changes in vitamin K₁ intake.

Keywords

Clinical trials - oral anticoagulants - vitamin K-dependent factors - clinical / epidemiological studies

• References

• 1 U.S. Preventive Services Task Force. Routine vitamin supplementation to prevent cancer and cardiovascular disease: Recommendations and rationale. Ann Intern Med. 2003; 139: 51-5.
• 2 American Heart Association. Vitamins and mineral supplements. AHA Scientific Position. Accessed on May 25, 2004 at http://www.americanheart.org/presenter.jhtml? identifier=4788.
• 3 American Dietetic Association. Position of the American Dietetic Association: food fortification and dietary supplements. J Am Diet Assoc 2001; 101: 115-25.
• 4 Slesinski MJ, Subar AF, Kahle LL. Trends in use of vitamin and mineral supplements in the United States: the 1987 and 1992 National Health Interview Surveys. J Am Diet Assoc 1995; 95: 921-3.
• 5 Balluz LS, Kieszak SM, Philen RM. et al. Vitamin and mineral supplement use in the United States. Results from the Third National Health and Nutrition Examination Survey. Arch Fam Med 2000; 09: 258-62.
• 6 Harris JE. Interaction of dietary factors with oral anticoagulants: review and applications. J Am Diet Assoc 1995; 95: 580-4.
• 7 Lubetsky A, Dekel-Stern E, Chetrit A. et al. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 1999; 81: 396-9.
• 8 Karlson B, Leijd B, Hellström K. On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. Acta Med Scand 1986; 220: 347-50.
• 9 Pedersen FM, Hamberg O, Hess K. et al. The effect of dietary vitamin K on warfarininduced anticoagulation. J Intern Med 1991; 229: 517-20.
• 10 Kurnik D, Lubetsky A, Loebstein R. et al. Multivitamin supplements may affect warfarin anticoagulation in susceptible patients. Ann Pharmacother 2003; 37: 1603-6.
• 11 Hirsh J, Dalen JE, Anderson DR. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
• 12 Hylek EM, Heiman H, Skates SJ. et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279: 657-62.
• 13 Davidson KW, Sadowski JA. Determination of vitamin K compounds in plasma or serum by high-performance liquid chromatography using postcolumn chemical reduction and fluorimetric detection. Methods Enzymol 1997; 284: 408-21.
• 14 Absher RK, Moore ME, Parker MH. Patientspecific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002; 36: 1512-7.
• 15 Cushman M, Booth SL, Possidente CJ. et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112: 572-7.
• 16 Franco V, Polanczyk CA, Clausell N. et al. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective vidence from observational and randomized protocols. Am J Med 2004; 11: 651-6.
• 17 Chow WH, Chow TC, Tse TM. et al. Anticoagulation instability with life-threatening complication after dietary modification. Postgrad Med J 1990; 66: 855-7.
• 18 Walker FB. Myocardial infarction after diet-induced warfarin resistance. Arch Intern Med 1984; 144: 2089-90.
• 19 Qureshi GD, Reinders TP, Swint JJ. et al. Acquired warfarin resistance and weightreducing diet. Arch Intern Med 1981; 141: 507-9.
• 20 Watson AJ, Pegg M, Green JR. Enteral feeds may antagonize warfarin. Br Med J 1984; 288: 557.
• 21 Kempin SJ. Warfarin resistance caused by broccoli. N Engl J Med 1983; 308: 1229-30.
• 22 Ansell J, Hirsh J, Dalen J. et al. Managing oral anticoagulant therapy. Chest 2001; 119: 22S-38S.
• 23 McKeown NM, Jacques PF, Gundberg CM. et al. Dietary and nondietary determinants of vitamin K biochemical measures in men and women. J Nutr 2002; 132: 1329-34.
• 24 Schulman S. Clinical practice: Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349: 675-83.
• 25 Bovill EG, Fung M, Cushman M. Vitamin K and oral anticoagulation: Thought for food. Am J Med 2004; 116: 711-3.
• 26 Kamali F, Edwards C, Butler TJ. et al. The influence of the (R)-and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation. Thromb Haemost 2000; 84: 39-42.
• 27 Loebstein R, Yonath H, Peleg D. et al. Interindividual variability in sensitivity to warfarin – nature or nurture?. Clin Pharmacol Ther 2001; 70: 159-64.